Teva, Active Biotech to begin Phase III study of Oral Laquinimod
The companies are to initiate a third Phase III study of laquinimod, following the written agreement reached with the FDA on the Special Protocol Assessment. Teva Pharmaceutical Industries
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.